BioCryst Pharmaceuticals, Inc. (BCRX) has a consensus analyst rating of Buy, based on 29 analysts covering the stock. Of those, 25 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for BCRX is $16.00, representing a +65.5% upside from the current price of $9.67. Price targets range from a low of $9.00 to a high of $25.00.
